vs

Side-by-side financial comparison of Colgate-Palmolive (CL) and Exelon (EXC). Click either name above to swap in a different company.

Exelon is the larger business by last-quarter revenue ($5.4B vs $5.3B, roughly 1.0× Colgate-Palmolive). On growth, Colgate-Palmolive posted the faster year-over-year revenue change (8.4% vs -19.4%). Over the past eight quarters, Colgate-Palmolive's revenue compounded faster (2.6% CAGR vs 0.5%).

The Colgate-Palmolive Company, commonly known as Colgate-Palmolive, is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. The company specializes in the production, distribution, and provision of household, health care, personal care, and veterinary products.

Exelon Corporation is an American public utility headquartered in Chicago, and incorporated in Pennsylvania. Exelon is the largest electric parent company in the United States by revenue and is the largest regulated electric utility in the United States with approximately 10 million customers. The company is ranked 187th on the Fortune 500.

CL vs EXC — Head-to-Head

Bigger by revenue
EXC
EXC
1.0× larger
EXC
$5.4B
$5.3B
CL
Growing faster (revenue YoY)
CL
CL
+27.8% gap
CL
8.4%
-19.4%
EXC
Faster 2-yr revenue CAGR
CL
CL
Annualised
CL
2.6%
0.5%
EXC

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CL
CL
EXC
EXC
Revenue
$5.3B
$5.4B
Net Profit
$646.0M
Gross Margin
60.6%
Operating Margin
18.1%
21.9%
Net Margin
12.1%
Revenue YoY
8.4%
-19.4%
Net Profit YoY
-6.4%
EPS (diluted)
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CL
CL
EXC
EXC
Q1 26
$5.3B
$5.4B
Q4 25
$5.2B
$5.4B
Q3 25
$5.1B
$6.7B
Q2 25
$5.1B
$5.4B
Q1 25
$4.9B
$6.7B
Q4 24
$4.9B
$5.5B
Q3 24
$5.0B
$6.2B
Q2 24
$5.1B
$5.4B
Net Profit
CL
CL
EXC
EXC
Q1 26
$646.0M
Q4 25
$-36.0M
$594.0M
Q3 25
$735.0M
$875.0M
Q2 25
$743.0M
$391.0M
Q1 25
$690.0M
$908.0M
Q4 24
$738.0M
$647.0M
Q3 24
$737.0M
$707.0M
Q2 24
$731.0M
$448.0M
Gross Margin
CL
CL
EXC
EXC
Q1 26
60.6%
Q4 25
60.2%
Q3 25
59.4%
Q2 25
60.1%
Q1 25
60.8%
Q4 24
60.3%
Q3 24
61.1%
Q2 24
60.6%
Operating Margin
CL
CL
EXC
EXC
Q1 26
18.1%
21.9%
Q4 25
1.7%
21.9%
Q3 25
20.6%
22.4%
Q2 25
21.1%
17.1%
Q1 25
21.9%
22.9%
Q4 24
21.5%
20.0%
Q3 24
21.2%
19.4%
Q2 24
21.6%
17.0%
Net Margin
CL
CL
EXC
EXC
Q1 26
12.1%
Q4 25
-0.7%
11.0%
Q3 25
14.3%
13.0%
Q2 25
14.5%
7.2%
Q1 25
14.1%
13.5%
Q4 24
14.9%
11.8%
Q3 24
14.6%
11.5%
Q2 24
14.5%
8.4%
EPS (diluted)
CL
CL
EXC
EXC
Q1 26
$0.80
Q4 25
$-0.04
Q3 25
$0.91
$0.86
Q2 25
$0.91
$0.39
Q1 25
$0.85
$0.90
Q4 24
$0.89
Q3 24
$0.90
$0.70
Q2 24
$0.89
$0.45

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CL
CL
EXC
EXC
Cash + ST InvestmentsLiquidity on hand
$1.3B
$626.0M
Total DebtLower is stronger
$49.4B
Stockholders' EquityBook value
$28.8B
Total Assets
$16.6B
$116.6B
Debt / EquityLower = less leverage
1.72×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CL
CL
EXC
EXC
Q1 26
$1.3B
$626.0M
Q4 25
$1.4B
$626.0M
Q3 25
$1.3B
$1.5B
Q2 25
$1.2B
$724.0M
Q1 25
$1.1B
$1.0B
Q4 24
$1.3B
$357.0M
Q3 24
$1.2B
$616.0M
Q2 24
$1.1B
$934.0M
Total Debt
CL
CL
EXC
EXC
Q1 26
$49.4B
Q4 25
$7.8B
$49.4B
Q3 25
Q2 25
Q1 25
Q4 24
$7.0B
$44.7B
Q3 24
Q2 24
Stockholders' Equity
CL
CL
EXC
EXC
Q1 26
$28.8B
Q4 25
$54.0M
$28.8B
Q3 25
$856.0M
$28.1B
Q2 25
$702.0M
$27.6B
Q1 25
$363.0M
$27.6B
Q4 24
$212.0M
$26.9B
Q3 24
$435.0M
$26.6B
Q2 24
$123.0M
$26.2B
Total Assets
CL
CL
EXC
EXC
Q1 26
$16.6B
$116.6B
Q4 25
$16.3B
$116.6B
Q3 25
$17.5B
$113.5B
Q2 25
$17.5B
$111.1B
Q1 25
$16.6B
$109.5B
Q4 24
$16.0B
$107.8B
Q3 24
$16.8B
$106.1B
Q2 24
$16.5B
$105.1B
Debt / Equity
CL
CL
EXC
EXC
Q1 26
1.72×
Q4 25
145.17×
1.72×
Q3 25
Q2 25
Q1 25
Q4 24
33.04×
1.66×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CL
CL
EXC
EXC
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$609.0M
FCF MarginFCF / Revenue
11.4%
Capex IntensityCapex / Revenue
2.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$3.8B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CL
CL
EXC
EXC
Q1 26
Q4 25
$1.5B
$1.2B
Q3 25
$1.3B
$2.3B
Q2 25
$884.0M
$1.5B
Q1 25
$600.0M
$1.2B
Q4 24
$1.3B
$1.4B
Q3 24
$1.2B
$1.7B
Q2 24
$990.0M
$1.5B
Free Cash Flow
CL
CL
EXC
EXC
Q1 26
$609.0M
Q4 25
$1.3B
$-1.2B
Q3 25
$1.1B
$163.0M
Q2 25
$776.0M
$-502.0M
Q1 25
$476.0M
$-746.0M
Q4 24
$1.1B
$-510.0M
Q3 24
$1.0B
$-6.0M
Q2 24
$873.0M
$-237.0M
FCF Margin
CL
CL
EXC
EXC
Q1 26
11.4%
Q4 25
24.4%
-22.0%
Q3 25
21.6%
2.4%
Q2 25
15.2%
-9.3%
Q1 25
9.7%
-11.1%
Q4 24
21.9%
-9.3%
Q3 24
20.5%
-0.1%
Q2 24
17.3%
-4.4%
Capex Intensity
CL
CL
EXC
EXC
Q1 26
2.6%
Q4 25
3.4%
45.0%
Q3 25
3.0%
31.9%
Q2 25
2.1%
37.1%
Q1 25
2.5%
29.0%
Q4 24
3.7%
35.4%
Q3 24
2.7%
27.5%
Q2 24
2.3%
31.7%
Cash Conversion
CL
CL
EXC
EXC
Q1 26
Q4 25
2.09×
Q3 25
1.72×
2.63×
Q2 25
1.19×
3.86×
Q1 25
0.87×
1.32×
Q4 24
1.72×
2.20×
Q3 24
1.58×
2.39×
Q2 24
1.35×
3.26×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CL
CL

Latin America$1.3B25%
Pet Nutrition$1.2B22%
Europe, Middle East & Africa (1)$1.1B21%
North America (1)$888.0M17%
Asia Pacific (1)$804.0M15%

EXC
EXC

Segment breakdown not available.

Related Comparisons